Lv11
48 积分 2023-02-10 加入
Final overall survival analysis and exploratory biomarker study from JUPITER-06: a randomized phase III trial of toripalimab plus chemotherapy in advanced esophageal squamous-cell carcinoma
7天前
已完结
Fruquintinib plus paclitaxel versus placebo plus paclitaxel for gastric or gastroesophageal junction adenocarcinoma: the randomized phase 3 FRUTIGA trial
7天前
已完结
Enlonstobart (SG001) plus platinum-based chemotherapy ± bevacizumab for first-line treatment of PD-L1 positive recurrent/metastatic cervical cancer: Safety run-in results of phase III randomized, double-blind, placebo-controlled study
7天前
已完结
Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial
13天前
已完结
Aumolertinib with or without chemotherapy in EGFR-mutated advanced non-small-cell lung cancer (AENEAS2): an open-label, multicentre, randomised, controlled, phase 3 trial
14天前
已完结
OA05.02 First-Line Atezolizumab Plus Chemotherapy in Elderly Patients With Advanced NSCLC, IFCT-1805 Elderly: A Randomized, Multicenter, Phase 3 Trial
20天前
已完结
PL03.10 Adjuvant Chemotherapy (CT) vs CT-immunotherapy for R0 Stage IB-IIIA NSCLC Patients (NADIM ADJUVANT): a Randomized, Phase 3 Trial
20天前
已关闭
MA04.09 Patterns of Progression and Recurrence with Perioperative Durvalumab in Patients with Resectable NSCLC from AEGEAN
20天前
已关闭
MA04.08 Perioperative Tislelizumab for Resectable Non-small Cell Lung Cancer: Final Analysis of RATIONALE-315
20天前
已完结
Durvalumab with carboplatin/paclitaxel and bevacizumab followed by durvalumab and bevacizumab with or without olaparib maintenance in newly diagnosed non-BRCA-mutated advanced ovarian cancer
26天前
已完结
皖公网安备34019202002308
